Fennec Pharmaceuticals Inc. (FENC): who owns it and who trades it
As of Nov 16, 2026, FENC insiders reported 18 open-market sales worth $10.8M and no purchases in the last 12 months, with 20% of the sale value made under pre-set 10b5-1 plans. The largest seller was Southpoint Capital Advisors LP (10% owner), with $7.5M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Fennec Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns FENC
105 funds and institutions reported FENC shares worth $176M at the end of Q2 2026, about 48% of the company. The largest holder is Rosalind Advisors, Inc. with 9.2%.
Funds and institutions (13F) 48%Everyone else 52%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3.19M | 9.25% | $34.3M | +10% |
| AIGH Capital Management LLC | 2.49M | 7.21% | $26.7M | +25% |
| Solas Capital Management, LLC | 1.89M | 5.48% | $20.3M | -24% |
| BlackRock, Inc. | 1.73M | 5.01% | $18.6M | +26% |
| AWM Investment Company, Inc. | 1.16M | 3.37% | $12.5M | +61% |
| Vanguard Capital Management LLC | 839,306 | 2.43% | $9M | -6% |
| Prospect Capital Advisors, LLC | 497,800 | 1.44% | $5.4M | New |
| State Street Corp | 426,004 | 1.24% | $4.6M | +19% |
| Geode Capital Management, LLC | 402,566 | 1.17% | $4.3M | +8% |
| Jane Street Group, LLC | 233,877 | 0.68% | $2.5M | New |
| Potomac Capital Management, Inc. | 224,400 | 0.65% | $2.4M | No change |
| Morgan Stanley | 221,920 | 0.64% | $2.4M | +5% |
| Vanguard Portfolio Management LLC | 199,998 | 0.58% | $2.1M | +19% |
| Northern Trust Corp | 167,922 | 0.49% | $1.8M | +10% |
| Marshall Wace, LLP | 138,758 | 0.40% | $1.5M | New |
| Renaissance Technologies LLC | 134,200 | 0.39% | $1.4M | New |
| Nuveen, LLC | 131,482 | 0.38% | $1.4M | +116% |
| Trexquant Investment LP | 119,122 | 0.35% | $1.3M | +130% |
| CenterBook Partners LP | 118,582 | 0.34% | $1.3M | New |
| Lion Point Capital, LP | 112,434 | 0.33% | $1.2M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, FENC insiders reported $0 of open-market purchases and $10.8M of sales. 20% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Marco Maria Brughera | Director | Sale plan | 20,000 | $12.00 | $240K | Form 4 |
| Sep 15, 2026 | Marco Maria Brughera | Director | Sale plan | 15,545 | $10.29 | $160K | Form 4 |
| Sep 1, 2026 | Rosty Raykov | Other | Sale plan | 10,000 | $12.11 | $121K | Form 4 |
| Aug 31, 2026 | Pierre Sargis Sayad | Chief Medical Officer | Sale | 12,000 | $12.18 | $146K | Form 4 |
| Aug 27, 2026 | Robert Andrade | CFO | Sale plan | 75,000 | $11.78 | $884K | Form 4 |
| Aug 3, 2026 | Rosty Raykov | Other | Sale plan | 10,000 | $9.58 | $95.8K | Form 4 |
| Jul 1, 2026 | Rosty Raykov | Other | Sale plan | 9,599 | $10.41 | $99.9K | Form 4 |
| Jun 1, 2026 | Rosty Raykov | Director | Sale plan | 9,747 | $9.62 | $93.8K | Form 4 |
| May 11, 2026 | Chris A Rallis | Director | Sale plan | 8,346 | $7.04 | $58.8K | Form 4 |
| May 1, 2026 | Rosty Raykov | Director | Sale plan | 10,781 | $6.47 | $69.8K | Form 4 |
| Apr 1, 2026 | Rosty Raykov | Director | Sale plan | 10,946 | $6.31 | $69.1K | Form 4 |
| Mar 2, 2026 | Rosty Raykov | Director | Sale plan | 10,079 | $8.36 | $84.3K | Form 4 |
| Feb 2, 2026 | Rosty Raykov | Director | Sale plan | 10,349 | $7.76 | $80.3K | Form 4 |
| Jan 2, 2026 | Rosty Raykov | Director | Sale plan | 10,312 | $7.60 | $78.4K | Form 4 |
| Dec 24, 2025 | Southpoint Capital Advisors LP +4 | 10% owner | Sale | 1.00M | $7.50 | $7.5M | Form 4 |
| Dec 5, 2025 | Rosty Raykov | Director | Sale plan | 10,000 | $7.54 | $75.4K | Form 4 |
| Nov 18, 2025 | Southpoint Capital Advisors LLC +4 | 10% owner | Sale | 19,341 | $8.79 | $170K | Form 4 |
| Nov 17, 2025 | Southpoint GP, LLC +4 | 10% owner | Sale | 85,918 | $8.79 | $755K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Southpoint Capital Advisors LP | 10% owner | – | $7.5M | Dec 24, 2025 |
| Robert Andrade | CHIEF FINANCIAL OFFICER | – | $884K | Aug 27, 2026 |
| Rosty Raykov | Director | – | $868K | Sep 1, 2026 |
| Southpoint GP, LLC | 10% owner | – | $755K | Nov 17, 2025 |
| Marco Maria Brughera | Director | – | $400K | Nov 13, 2026 |
| Southpoint Capital Advisors LLC | 10% owner | – | $170K | Nov 18, 2025 |
| Pierre Sargis Sayad | Chief Medical Officer | – | $146K | Aug 31, 2026 |
| Chris A Rallis | Director | – | $58.8K | May 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
FENC short interest
Low short interest. 1.3% of FENC shares are sold short: about 1 share in 77. Over the last 12 reports the number of shares short went down 27%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 454,453 FENC shares were sold short, 1.3% of the shares outstanding, down 6.8% from the report before. At the average daily volume of 116,848 shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 454,453 | 1.30% | -7% | 116,848 | 3.9 |
| Oct 15, 2026 | 487,514 | 1.39% | -5% | 129,085 | 3.8 |
| Sep 30, 2026 | 513,287 | 1.46% | -6% | 133,171 | 3.9 |
| Sep 15, 2026 | 545,039 | 1.55% | +5% | 258,376 | 2.1 |
| Aug 31, 2026 | 520,659 | 1.48% | -2% | 255,867 | 2.0 |
| Aug 14, 2026 | 532,095 | 1.52% | -14% | 245,478 | 2.2 |
| Jul 31, 2026 | 615,869 | 1.79% | +1% | 115,860 | 5.3 |
| Jul 15, 2026 | 609,189 | 1.77% | +25% | 182,924 | 3.3 |
| Jun 30, 2026 | 488,731 | 1.42% | +8% | 366,003 | 1.3 |
| Jun 15, 2026 | 450,578 | 1.31% | -10% | 224,711 | 2.0 |
| May 29, 2026 | 498,119 | 1.44% | -20% | 355,955 | 1.4 |
| May 15, 2026 | 623,377 | 1.81% | -41% | 386,241 | 1.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Fennec Pharmaceuticals company events
Fennec Pharmaceuticals filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Sep 17, 2026.
- Sep 17, 2026AnnouncementFennec Pharmaceuticals Inc. announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity. A copy of… Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 22, 2026AnnouncementFennec Pharmaceuticals Inc. announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program. A copy of the press release is… Filing
- May 18, 2026LeadershipThe Compensation Committee of the Board of Directors of Fennec Pharmaceuticals Inc. approved grants of stock options to purchase an aggregate of 50,000 common shares to three new employees under the Company’s 2026 Equity Inducement Plan, with a grant date of May 18, 2026, as inducement awards… Filing
- Apr 28, 2026LeadershipRostislav Raykov notified Fennec Pharmaceuticals Inc. of his desire to retire from the Company's Board of Directors and that he will not stand for re-election at the Company's 2026 annual meeting of shareholders. Filing
- Apr 22, 2026AnnouncementFennec Pharmaceuticals Inc. issued a press release announcing that four abstracts evaluating PEDMARK ® (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. A copy of the press release is… Filing
- Apr 7, 2026AnnouncementFennec Pharmaceuticals Inc. announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK ® (sodium thiosulfate injection) in adolescent and young adult and adult patients with head and neck and testicular cancers receiving cisplatin.… Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Mar 16, 2026AnnouncementFennec Pharmaceuticals Inc. entered into a License Agreement with Cipla Limited and Cipla USA, Inc. (together, “Cipla”) to resolve the litigation between the Company and Cipla relating to Cipla’s application to the U.S. Food and Drug Administration to market a generic version of the Company’s… Filing
- Mar 4, 2026AnnouncementFennec Pharmaceuticals Inc. announced that the Tampa General Hospital Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection (PEDMARK ® ) in reducing the risk of ototoxicity in adolescent and young adult and adult cancer patients receiving… Filing
- Feb 20, 2026AnnouncementFennec Pharmaceuticals Inc. announced that real-world data supporting the potential use of PEDMARK ® (sodium thiosulfate injection) in adults with head and neck cancers were presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium held February 19–21, 2026. The data, derived from a… Filing
- Dec 9, 2025AnnouncementFennec Pharmaceuticals Inc. announced the planned initiation of an investigator-sponsored clinical study to be conducted by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK ® (sodium thiosulfate injection) for the prevention of cisplatin-induced ototoxicity in… Filing
- Dec 2, 2025AnnouncementFennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK ® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young… Filing
- Nov 19, 2025AgreementAs previously disclosed, on August 1, 2022, Fennec Pharmaceuticals Inc. entered into a Securities Purchase Agreement with Petrichor Opportunities Fund I LP pursuant to which the Company previously issued POF and Petrichor Opportunities Fund I Intermediate LP (together with POF, collectively… Filing
- Nov 18, 2025AgreementFennec Pharmaceuticals Inc. entered into common share subscription agreements (each, a “Subscription Agreement” and collectively, the “Subscription Agreements”) with certain of its existing institutional shareholders and affiliated entities resident in the provinces of Canada (except Quebec)… Filing
- Nov 17, 2025AgreementFennec Pharmaceuticals Inc. entered into an underwriting agreement with Piper Sandler & Co. and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and sell an aggregate of 4,666,667 common shares, no par value… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Fennec Pharmaceuticals financials
Famous investors that hold FENC
4 of the 50 well-known investors we track reported holding FENC in their latest 13F filing. The largest position is Ken Griffin's, worth $1.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 165,832 | $1.8M | 0.0% | +133% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 137,400 | $1.5M | 0.0% | +2% |
| Israel Englander · Millennium Management | Q3 2026 | 37,155 | $396K | 0.0% | +41% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 33,414 | $356K | 0.0% | -41% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named FENC in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Sonic Fund II, L.P. | 13G/A | 4.1% |
| Nov 16, 2026 | Solas Capital Management, LLC | 13G/A | 4.1% |
| Nov 16, 2026 | Solas Capital Management, LLC | 13G/A | 4.1% |
| Nov 16, 2026 | Sonic Fund II, L.P. | 13G/A | 4.1% |
| Oct 19, 2026 | Orin Hirschman | 13G/A | 7.1% |
| Oct 19, 2026 | Orin Hirschman | 13G/A | 7.1% |
Questions about Fennec Pharmaceuticals Inc. (FENC) stock
Who owns the most FENC stock?
The largest reported owner of Fennec Pharmaceuticals Inc. (FENC) is Rosalind Advisors, Inc., with 9.2% of the company. In total, 105 funds and institutions reported holding FENC at the end of Q2 2026, together about 48% of the shares. See the largest owners.
Are FENC insiders buying or selling?
In the last 12 months, FENC insiders reported no open-market purchases and 18 sales worth $10.8M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in FENC?
As of Oct 30, 2026, 454,453 FENC shares were sold short, 1.3% of the shares outstanding, down 6.8% from the report before. At the average daily volume of 116,848 shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold FENC?
4 of the 50 well-known investors we track reported FENC in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $1.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.